… defined according to vaccine product received, age, and month of full vaccination with … ,
and vaccine registry databases. We assessed vaccine effectiveness against Covid-19 from May …

… unless the vaccine is also … aged 65 years and over in future trials of COVID-19 vaccine
candidates; (ii) careful monitoring of vaccine efficacy in older age groups following vaccination. …

… efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive
two doses, 21 days apart, of either placebo or the BNT162b2 vaccine … RNA vaccine that …

… , placebo-controlled trial, to evaluate the efficacy, immunogenicity, and safety of NVX-CoV2373
in preventing Covid-19 in participants between the ages of 18 and 84 years in the United …

… COVID-19 vaccine in a Phase 3 trial. It is important to understand how different groups respond
to COVID-19 vaccines … For COVID-19, age-structured mathematical models with realistic …

… number of Covid-19 cases in the age groups ex… Covid-19 cases in the age groups. Among
the participants who received the BNT162b2 vaccine, five cases occurred in the age group …

… compared the efficacy and safety of five kinds of COVID-19 vaccines in different age groups
(… The primary endpoint of the effectiveness index was GMT. The primary endpoints of the …

… Vaccine efficacy against Covid-19 at 7 days or more after the … Covid-19 with onset 7 days or
more after the second dose … vaccine and in 16 placebo recipients (vaccine efficacy, 90.7%; 95…

… December 11, 2020, for Covid-19 prevention in persons 16 years of age or older. On May
10… 12 years of age or older on the basis of data presented in this report. Other vaccines against …

… The safety and efficacy of COVID-19 vaccines in the population that should most benefit
from them may only become apparent after they have been given. No pharmacovigilance …